Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    16257339 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Condition: Thoracic Neoplasms
Interventions: Drug: erlotinib;   Drug: gefitinib
2 Unknown  Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Docetaxel

Study has passed its completion date and status has not been verified in more than two years.